SWOG clinical trial number
S0424
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
100% Accrual
Accrual
100%
Closed
100% Accrual
Accrual
100%
Abbreviated Title
Molecular Epidemiology
Participants
NCORP,
Members, Medical Oncologists, Pathologists, ECOG, NCCTG, RTOG, CALGB, CTSU
Research committees
Lung Cancer
Molecular Epidemiology
Pts must have newly diagnosed, primary, histologically confirmed Stage I, II, IIIA or IIIB (T4 or N3, excluding patients w/ malignant pleural effusion) NSCLC; Pts w/effusion are eligible if: a)fluid tapped is benign cytology and all physicians concur that it is from a benign etiology, b) fluid present after mediastinoscopy or thoracotomy, but not before, c) fluid deemed too small to tap under CT or U/S guidance; May be registered concurrently to a therapeutic study but not required to be on a therapeutic study; Must have tumor block/slides available and willing to provide tissue and blood sample for testing; Must have specific tissue specimens available as outlined in Section 4.2; Able and willing to complete the Lung Cancer Epidemiology Questionnaire and able to read and understand English; Must be identified and registered w/in 120 days of diagnosis; Must be willing to provide smoking history; Pts must not have diagnosis by cytology alone; Pts must not have malignant pleural effusion; Pts must not have other prior malignancy except for treated basal cell (or squamous cell) skin ca or in situ cervical ca; Pts must not have prior systemic chemotherapy or RT for cancer; Pts must not have pericardial effusions-if CT shows effusion then a negative echo must be confirmed OR effusion must be from a recent sx or other documented benign cause. NOTE: Pts registered concurrently to therapeutic trials must have blood and tissue obtained PRIOR to administration of ANY therapeutic agent(s).
0.5 Cancer Control Credits
2010
KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424
PC Mack;M Redman;K Chansky;S Matsumoto;W Holland;P Lara;C Ambrosone;DR Gandara Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 7013); ASCO annual meeting; poster
2009
Biomarkers of polycyclic aromatic hydrocarbon-DNA damage and cigarette smoke exposure
RM Santella;Y-J Zhang;Q Wang;M Redman;M Reid;W Davis;DR Gandara;C Powell;K Albain;C Ambrosone Journal of Thoracic Oncology, 4(9):suppl. 1, abst M39.2, S164 (IASLC 13th World Conf of Lung Cancer, oral presentation);
Molecular epidemiology of lung cancer
CB Ambrosone Journal of Thoracic Oncology 4(9):suppl 1, abst. M38.5, S163 (oral pres., IASLC 13th World Conf of Lung Cancer)
Role of EGFR pathway activation in never smoking patients with lung cancer
PC Mack Journal of Thoracic Oncology 4(9):suppl 1, abst. M39.3, S164 (oral presentation, 13th World Conference of Lung Cancer)
2008
Molecular epidemiology to better predict lung cancer risk
M Reid;RM Santella;CB Ambrosone Clinical Lung Cancer 9(3):149-153
PMid: PMID18621624 | PMC number: Review article not within scope of Public Access Policy
Cooperative group research efforts in lung cancer: focus on early stage non-small cell lung cancer
H Wakelee;C Langer;E Vokes;J Schiller;P Bass;N Saijo;A Adjei;F Shepherd;H Choy;DR Gandara Clinical Lung Cancer 9(1):9-15
PMid: PMID18282352 | PMC number: (Reviews are not within the scope of the Public Access )
